Sélectionner la langue
DRD1
DRD1 Informations sur la molécule
| Nom anglais | Dopamine D1 receptor | Nombre de médicaments commercialisés | 10 |
| Nombre de médicaments cliniques | 15 | Alias de la cible | D(1A) dopamine receptor，DRD1，Dopamine Receptor D1，Dopamine D1 Receptor，DRD1A，DADR，Receptors， Dopamine D1 |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Dopamine D1 receptor |
| Alias de la cible | D(1A) dopamine receptor，DRD1，Dopamine Receptor D1，Dopamine D1 Receptor，DRD1A，DADR，Receptors， Dopamine D1 |
| Nombre de médicaments commercialisés | 10 |
| Nombre de médicaments cliniques | 15 |
| Phase de R&D la plus avancée | Approved |
DRD1 Liste de produits
- Attribut
Protein (1)
- Bibliothèque de produits
En ligne (1)
- Espèces
Human (1)
- Étiquette
- (1)
- Marqueur
Unconjugated (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
DR1-H52P6 |  Human | HEK293 | Human DRD1 Full Length Protein (VLP) |  |  Ajouter au panier |
Quantité totale1
- 1
DRD1Contexte de la molécule
The dopamine receptor D1 (Drd1) is a member of the D1-like receptor family and is the most abundant dopamine receptor in the central nervous system. The receptor is found in the cortex, striatum and limbic system of the brain and the cardiovascular system.
DRD1Alias de la molécule
DRD1,Dopamine D1 receptor,D1R; DADR; DRD1A
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Ecopipam | PSYRX-101; Sch-39166 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Childhood-Onset Fluency Disorder; Gambling; Language Disorders; Lesch-Nyhan Syndrome; Self-Injurious Behavior; Speech Disorders; Stuttering; Tourette Syndrome | Details |
| Olanzapine transdermal patch (Starton Therapeutics) | CMIO-OLANZ; CHEMIO OLANZ; CMIO-OLNZ; STAR-OLZ | Phase 3 Clinical | Starton Therapeutics Inc | Nausea; Vomiting | Details |
| Olanzapine/samidorphan (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Schizophrenia | Details | |
| PF-06412562 | PF-6412562; PF-06412562; PF-2562; CVL-562 | Phase 2 Clinical | Pfizer Inc | Parkinson Disease; Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders | Details |
| Mevidalen | LY-3154207 | Phase 2 Clinical | Eli Lilly And Company | Alzheimer Disease; Lewy Body Disease; Parkinson Disease | Details |
| TGOF02N | TGOF-02N; TGOF02N; FKF02SC | Phase 2 Clinical | Fabre-Kramer | Schizophrenia | Details |
| Docarpamine (Martin Pharmaceuticals) | Phase 2 Clinical | Martin Pharmaceuticals Inc | Gastrointestinal Diseases; Liver Cirrhosis; Mouth Diseases | Details | |
| Glovadalen | UCB-0022 | Phase 2 Clinical | Ucb Biopharma Srl | Parkinson Disease | Details |
| [11C]NNC-112 | [11C]NNC-112 | Phase 2 Clinical | Glaxosmithkline Plc | Diagnostic agents | Details |
| Lu-AF-28996 | Phase 1 Clinical | H. Lundbeck A/S | Parkinson Disease | Details | |
| asenapine schizophrenia (Livzon Pharmaceutical/LTS Lohmann Therapie-Systeme) | Phase 1 Clinical | Lts Lohmann Therapie-Systeme Ag | Schizophrenia | Details | |
| Olanzapine intranasal (Neurelis) | NRL-4; NRL-1004 | Phase 1 Clinical | Neurelis Inc | Bipolar Disorder | Details |
| Oxytocin/Methylergometrine Maleate | Phase 1 Clinical | Nanjing Gritpharma Co Ltd | Hemorrhage; Obstetric Labor Complications | Details | |
| ITI-333 | ITI-333 | Phase 1 Clinical | Intra-Cellular Therapies Inc | Mood Disorders; Opioid-Related Disorders; Pain | Details |
| PF-06730110 | PF-06730110; [18F]MNI-968 | Phase 1 Clinical | Invicro Llc | Nerve Degeneration | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Docarpamine | TA-870; TA-8704 | Approved | Tanadopa | Heart Failure | null | 1994-01-01 | Heart Failure | Details | ||
| Olanzapine/Fluoxetine hydrochloride | OFC | Approved | Eli Lilly And Company | Symbyax | Mainland China | Bipolar I Disorder | Jiangsu Changtai Pharmaceutical Co Ltd | 2003-12-24 | Bipolar Disorder; Bipolar I Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant | Details |
| Zuclopenthixol Hydrochloride | LU-0108 | Approved | Clopixol | Bipolar Disorder; Schizophrenia | null | 1962-01-01 | Bipolar Disorder; Schizophrenia | Details | ||
| Methylergometrine Maleate | Approved | Metenarin, Methergine, Ryegonivin, Basofortina, Methylergobrevin | Japan | Postpartum Hemorrhage | Aska Pharmaceutical Co Ltd | 1971-05-01 | Postpartum Hemorrhage; Uterine Cervical Incompetence; Uterine Hemorrhage; Uterine Inertia | Details | ||
| Samidorphan/Olanzapine | ALKS-3831 | Approved | Alkermes Plc | Lybalvi | United States | Bipolar Disorder; Schizophrenia | Alkermes Inc | 2021-05-28 | Alcoholism; Bipolar and Related Disorders; Bipolar Disorder; Bipolar I Disorder; Psychotic Disorders; Schizophrenia | Details |
| Olanzapine | ALKS-7921; LY-170052; LY-170053; INP-105; BR-5402; QLG-2072; QLG2072 | Approved | Eli Lilly And Company | Zyprexa Zydis, Zyprexa Relprevv, Olansek, Zalasta, Zyprexa, Zyprexa Velotab, Olanzapine ODF, Lanzac, Zypadhera, 再普乐, Midax | EU | Bipolar Disorder; Schizophrenia | null | 1996-09-27 | Anorexia; Anorexia Nervosa; Autistic Disorder; Biliary Tract Neoplasms; Bipolar Disorder; Bipolar I Disorder; Bipolar II Disorder; Borderline Personality Disorder; Cachexia; Carcinoma, Hepatocellular; Chemotherapy-induced nausea and vomiting; Colorectal Neoplasms; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Emergence Delirium; Esophageal Neoplasms; Fasting; Feeding and Eating Disorders; Gambling; Hematopoietic stem cell transplantation (HSCT); Insulin Resistance; Lung Neoplasms; Malaria, Falciparum; Multiple Myeloma; Nausea; Neoplasms; Opioid-Related Disorders; Postoperative Nausea and Vomiting; Schizophrenia; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Substance-Related Disorders; Tinnitus; Vomiting; Weight Loss | Details |
| Phenylpropanolamine Hydrochloride | Approved | Nasadec, Nasathera, Pararhinol | Nasal Obstruction | Details | ||||||
| Olanzapine Oral Soluble Film(Jiangsu Hansoh) | Approved | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Mainland China | Schizophrenia; Bipolar Disorder | Jiangsu Hansoh Pharmaceutical Group Co Ltd | 2020-11-24 | Bipolar Disorder; Schizophrenia | Details | ||
| Olanzapine Oral Soluble Film(Qilu Pharma) | Approved | Qilu Pharmaceutical Co Ltd | Mainland China | Bipolar Disorder; Schizophrenia | Qilu Pharmaceutical Co Ltd | 2021-01-19 | Bipolar Disorder; Schizophrenia | Details | ||
| Stepholidine | Approved | Mainland China | Attention Deficit Disorder with Hyperactivity; Tourette Syndrome; Migraine Disorders; Headache | null | 1995-01-01 | Attention Deficit Disorder with Hyperactivity; Headache; Migraine Disorders; Tourette Syndrome | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques
Partager vers :